1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GSK Tailors SWIFT Readout Towards Asthma Approval

 
• By Elizabeth Cairns

The twice-yearly depemokimab will soon head to the regulators, but it will need to succeed repeatedly if it is to make the £3bn peak sales GSK is hoping for.    

GSK

GSK plc has high hopes for depemokimab, having previously suggested that it could bring in peak sales of more than £3bn ($3.8bn). For that to happen the ultra-long-acting IL-5 inhibitor will have to hit in a suite of late-stage trials, but the UK group is off to a good start with the results of two asthma studies.

Key Takeaways
  • GSK’s IL-5 inhibitor depemokimab has hit in two Phase III trials in severe asthma

The twin Phase III trials SWIFT-1 and SWIFT-2, which assessed depemokimab in patients with severe asthma with type 2 inflammation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.